https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-07-10 / Int. J. Cancer 2004 Jul;110(5):730-40
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-07-10 / Int. J. Cancer 2004 Jul;110(5):730-402004-07-10 00:00:002019-02-15 09:20:01Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IV patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-07-01 / Leuk. Lymphoma 2004 Jul;45(7):1419-28
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-07-01 / Leuk. Lymphoma 2004 Jul;45(7):1419-282004-07-01 00:00:002019-02-15 08:51:04Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-07-01 / Hum. Pathol. 2004 Jul;35(7):881-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-07-01 / Hum. Pathol. 2004 Jul;35(7):881-62004-07-01 00:00:002019-02-15 08:36:24Dendritic cells, T-cell infiltration, and Grp94 expression in cholangiocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-06-08 / Cancer Immunol. Immunother. 2004 Sep;53(9):777-85
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-06-08 / Cancer Immunol. Immunother. 2004 Sep;53(9):777-852004-06-08 00:00:002019-02-15 08:50:26Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-06-07 / Int. Immunol. 2004 Jul;16(7):1037-52
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-06-07 / Int. Immunol. 2004 Jul;16(7):1037-522004-06-07 00:00:002019-02-15 09:15:21Dendritic cells generated in the presence of interferon-alpha stimulate allogeneic CD4+ T-cell proliferation: modulation by autocrine IL-10, enhanced T-cell apoptosis and T regulatory type 1 cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-06-01 / Int J Hyperthermia 2004 Jun;20(4):405-19
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-06-01 / Int J Hyperthermia 2004 Jun;20(4):405-192004-06-01 00:00:002019-02-15 09:17:50Thermal enhancement of oxaliplatin-induced inhibition of cell proliferation and cell cycle progression in human carcinoma cell lines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-05-01 / J. Neurosurg. 2004 May;100(5 Suppl Pediatrics):492-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-05-01 / J. Neurosurg. 2004 May;100(5 Suppl Pediatrics):492-72004-05-01 00:00:002021-11-15 15:38:16Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-05-01 / Int J Hyperthermia 2004 May;20(3):252-77
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-05-01 / Int J Hyperthermia 2004 May;20(3):252-772004-05-01 00:00:002019-02-15 08:35:13Feasibility of lung cancer hyperthermia using breathable perfluorochemical (PFC) liquids. Part I: Convective hyperthermia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-05-01 / J. Viral Hepat. 2004 May;11(3):217-24
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-05-01 / J. Viral Hepat. 2004 May;11(3):217-242004-05-01 00:00:002019-02-15 08:37:51Selective functional deficit in dendritic cell–T cell interaction is a crucial mechanism in chronic hepatitis B virus infection
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-05-01 / Br. J. Haematol. 2004 May;125(3):343-52
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-05-01 / Br. J. Haematol. 2004 May;125(3):343-522004-05-01 00:00:002019-02-15 08:51:06Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma
